THE CASSIOPEA STORY

That’s why we are driven to pursue better dermatology

Cassiopea S.p.A. is listed on the Swiss stock exchange (ticker: SKIN) with the vision of building a leading, fully integrated dermatology company. Cassiopea, Inc., our United States subsidiary, was created with the mission to commercialize Cassiopea’s products in the United States.

At Cassiopea, we are driven by the goal to treat persistent skin conditions, like acne, that have a long-term physical and emotional impact on lives and self-esteem.

Our current portfolio comprises 4 potentially groundbreaking clinical candidates, for which Cassiopea owns the worldwide rights. These product candidates are based on three new chemical entities (NCEs) and target unmet medical needs and opportunities in the medical dermatology market.

What do we believe?

That we are important partners in the delivery of patient care, and that our role includes drug development, education, service, access, and support to ensure that sufferers get the treatment options they need.

Why dermatology?

Because dermatology matters to healthcare providers who are forward-thinking and searching for new innovation to address essential conditions like acne and alopecia. When there’s progress in dermatology, magic happens. Patients gain confidence, change their outlook, and live better lives.

PIERPAOLO GUZZO

Chairman of the Board and Chief Executive Officer

Member of the Board of Directors since 2015, Chairman of the Board since April 2021 and starting from 30 January 2022 CEO, Guzzo is the founder and CEO of management consulting and investing firm EQValue Partners.

Specialized in Private Equity, M&A and management consulting. Pierpaolo has extensive experience in managing private equity deals as well acting as advisor on mergers, leveraged buy-outs, IPO’s, and restructuring projects.

Since 1998, regularly appointed in the corporate bodies of several Italian SME and large companies. Pierpaolo managed private equity investments and/or consulting projects in different sectors, including industrials, financial and business services, consumer & retail, energy, pharma, media, technology.

After completing his studies Pierpaolo started his career in 1993 at Arthur Andersen, where he worked for both the audit and the business consulting areas. In 1996 he joined the M&A Team of SOFIPA, an Italian Merchant Bank. In 1998 he joined the private equity team of ABN AMRO in Italy, where he served as Investment Manager. In 2000 he joined, as Director, PM & Partners SpA, a € 200 mln private equity fund focused on Italian companies. In 2008 he was founder and CEO of EQValue Corporate Partners.

Graduated in Business Administration at the University of Rome “La Sapienza” in 1991. Pierpaolo is CPA – Certified Public Accountant (“Dottore Commercialista”) and External Auditor (“Revisore Contabile”). Pierpaolo speaks Italian and English.

MARCO PASERO

Board Member and Chief financial Officer

MAURIZIO BALDASSARINI

Board Member (non-executive, independent)

Baldassarini is our Chartered Accountant and Auditor who has served on the Cassiopea Board of Directors since 2018. A technical advisor to the Court of Rome, he specializes in business valuation, financial-economic analysis, and business/investment plan development. He is also a founding partner at BOCG Associati, a management-consulting firm based in Italy.

During his career, Baldassarini has assisted with multiple merger and acquisition projects as well as corporate restructurings, serving primarily as a business and financial advisor. He has been appointed as an expert witness to the court of law in the field of transformations and corporate mergers and holds duties as board administrator and chair of the Italian Statutory Board of Auditors.

Baldassarini was a professor of Corporate Finance at the Sapienza University of Rome and a professor at various training institutions in Italy. He received a degree from the University of Rome in Economics and Business and has published several scientific monographs in corporate finance.

ANTONIO CARNEVALI

Board Member (non-executive, independent)

ROBERTO LAZZARONE

Board Member (non-executive, independent)

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.